Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Quanterix Corporation

< Previous 1 2 3 Next >
Quanterix’s First Quarter 2023 Earnings Conference Call
From Quanterix Corporation
Via Business Wire
Tickers QTRX
FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate in Barclays Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Present at Cowen’s 43rd Annual Health Care Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Announces Appointment of Brian Blaser to Board of Directors
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Corporation Releases Operating Results for Third Quarter 2022
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix’ Third Quarter 2022 Earnings Conference Call
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate in the Canaccord Genuity 42nd Annual Growth Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix’ Second Quarter 2022 Earnings Conference Call
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S.
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Corporation Releases Operating Results for First Quarter 2022
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate in the SVB Leerink Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Provides Operational and Preliminary Financial Highlights
From Quanterix Corporation
Via Business Wire
Tickers QTRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.